Engineering or inducing pdgf and/or pdgfr signaling to enhance nk cell therapy
AssigneeCity of Hope
InventorsJianhua Yu, Michael A. Caligiuri
Life of this patent
Estimating the term…
Abstract
Provided herein, inter alia, are genetically-modified natural killer (NK) cells capable of expressing platelet-derived growth factor (PDGF) and/or platelet-derived growth factor receptor (PDGFR); pharmaceutical compositions comprising the genetically-modified natural killer (NK) cells; methods of treating cancer with the genetically-modified natural killer (NK) cells; and methods of expanding a population of NK cells using PDGF.
Claims52
A genetically-modified NK cell that expresses:
- (i) platelet-derived growth factor (PDGF);
- (ii) platelet-derived growth factor receptor (PDGFR);
- or
- (iii) PDGF and PDGFR.
The genetically-modified NK cell of claim 22, wherein the genetically-modified NK cell comprises an exogenous nucleic acid that expresses tEGFR protein.
29, The NK cell of claim 1, wherein the genetically-modified NK cell does not comprise a CD19 chimeric antigen receptor (CAR).
A method of expanding a population of natural killer cells in vitro, the method comprising contacting the NK cells with an effective amount of platelet-derived growth factor D (PDGF-D).
Dependencies are inferred from the claim text.